Date: December 3-4, 2019
Location: Westin Grand Munich, Munich, Germany
Register Online: CLICK HERE TO REGISTER NOW - Save an extra 10% off* the current rate by using code D10-999-JDS20
Legal, Regulatory and Commercial Perspectives on the International Biosimilars Marketplace
The Global Biosimilars market is expected to grow robustly. Market watchers anticipate that Europe in particular will experience record growth in this area. A significant number of blockbuster biologic drugs are scheduled to lose patent protection within the next few years, thus creating new opportunity for the entrance of biosimilar drugs across the continent.
Join us at the Global Legal and Regulatory Summit on Biosimilars taking place in Munich on 3 - 4th December. Be part of an interactive discussions that will enable you to develop a holistic legal and regulatory strategy for maximizing commercial results for your organization or clients.
The complete agenda is now available - Download the Brochure Now »
This exclusive European event has been specifically designed for In-House IP Counsel and Directors, Strategists and Business Development Executives, as well as Regulatory Affairs Executives and attorneys operating within the biosimilars community.
Meet the Co-Chairs:
 |
 |
Lindsey Kent
Assistant General Patent Counsel
Eli Lilly |
Alexandra Moulson
Head Strategy, Portfolio and Program Management
PolPharma Biologics |
Please take a moment to hear Ms. Moulson explain why this event is important to the biosimilar stakeholders in Europe, the U.S. and worldwide. Watch video now »
Obtain Insights from Key Global Industry Stakeholders:
- Abbott Laboratories
- Alexion Pharma GmbH
- Amgen
- Biocon Research Limited
- Fresenius Kabi
- Formycon AG
- Glenmark Pharmaceuticals
- UCB Biopharma
- Also Featuring Alumni of Navartis, Teva, Sandoz
Government insights from Europe and the US:
German Patent and Trade Mark Office
U.S. Food and Drug Administration
Meet all the speakers and learn more about this conference » C5-Online.com/Biosimilars
Benefit from In-Depth Discussions which Will Help You:
- Understand how international affairs are influencing the future of biosimilar development and commercialization
- Analyse the business and legal repercussions of the EMA and FDA biosimilar approval processes
- Comprehend the importance of regulatory exclusivities in biosimilar development from the perspectives of innovators and generics
- Assess the effects of the current SPC landscape and manufacturing waiver on biosimilar patents
- Navigate the complexities of U.S. market entry: naming, labeling, and marketing considerations
- Evaluate the nuances of the Asian Biosimilars marketplace: Japan, Korea, China
- Develop innovative strategies to prevent compliance breaches of EU competition law
REGISTER NOW and save an extra 10% off* the conference by using code D10-999-JDS20
*Discount is valid for new registration only and it’s not applicable for workshops.
